Meeting: 2017 ASCO Annual Meeting Track: Gastrointestinal (Colorectal) Cancer Abstract number: 3503 Citation: J Clin Oncol 35, 2017 (suppl; abstr 3503) Authors: Alan P. Venook, Fang-Shu Ou, Heinz-Josef Lenz, et al. Background: 80405 found no OS or Progression Free Survival (PFS) difference when bevacizumab (BV) or cetuximab (Cet) was added to...
Pro zobrazení tohoto obsahu je třeba být přihlášen.